Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Capital Expenditures (2018 - 2021)

ENDRA Life Sciences (NDRA) has disclosed Capital Expenditures for 4 consecutive years, with $45000.0 as the latest value for Q1 2021.

  • Quarterly Capital Expenditures rose 101.34% to $45000.0 in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $45000.0 through Dec 2021, down 40.27% year-over-year, with the annual reading at $17280.0 for FY2025, 8.0% up from the prior year.
  • Capital Expenditures for Q1 2021 was $45000.0 at ENDRA Life Sciences, down from $64850.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $100000.0 in Q3 2018, with the low at -$11867.0 in Q3 2020.
  • Average Capital Expenditures over 4 years is $32991.0, with a median of $30353.5 recorded in 2019.
  • Peak annual rise in Capital Expenditures hit 326.61% in 2020, while the deepest fall reached 69.07% in 2020.
  • Over 4 years, Capital Expenditures stood at $100000.0 in 2018, then tumbled by 61.64% to $38357.0 in 2019, then soared by 69.07% to $64850.0 in 2020, then crashed by 30.61% to $45000.0 in 2021.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $45000.0, $64850.0, and -$11867.0 for Q1 2021, Q4 2020, and Q3 2020 respectively.